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ABSTRACT
Purpose
Cancer of uterine cervix is one of the leading malignancies affecting the South 
African female population. In recent years, High Dose Rate (HDR) brachytherapy in 
combination with External Beam Radiotherapy (EBRT) has been popular in the 
management of cancers of uterine cervix. Various fractionations regimens of HDR 
are used in different centres. This randomized prospective study reports the treatment 
results and incidence of bladder and rectal complications following radical treatment 
of carcinoma of cervix with standard EBRT and 2, 3 or 4 fractions of HDR
brachytherapy.
Methods and Materials
Sixty-six patients with biopsy proven stage IIB and stage IIIB cancer of cervix were 
recruited. All patients were treated radically and received EBRT 50 Gy in 25 
fractions at 2 Gy per fraction. Almost all patients received concomitant Cisplatin 80 
mg/m2 3 weekly. Patients were then randomized into one of the three-fractionation
regimens of HDR: 6.5 Gy  4; 8 Gy  3; and 9 Gy  2. Each HDR application was 
evaluated separately. AP and lateral radiographs were taken. ICRU rectum, bladder,
and PSW reference point were identified. Using the linear quadratic formula, the 
biologically effective dose to the tumour using an /β ratio of ten (Gy10) was 
calculated at point A in order to determine a dose response relationship for local 
control. The biologically effective dose to organs at risk was calculated using an /
ratio of 3 and this was used to assess the complication rates of the treatment. Patients
were evaluated using SOMA Lent toxicity criteria during the treatments, at 6 weeks 
and finally at 6 months when Pap-smears were performed to assess local control.
Results
Sixty-six patients were entered in this study. Fifty-nine completed chemo-
radiotherapy and attended both 6 weeks and 6 months follow up and evaluations. The 
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mean age of the patients was 51.6 years and the mean duration of the treatment was 
47.2 days. Of the 59 patients who completed treatment and had six months follow up,
29 patients were stage IIB and 30 were stage IIIB. The overall complete response rate 
for the whole group was 88%. The response rate was 90% in arm I, 85.7% in arm II,
and 88.8 in arm III, which was not statistically significant (p=0.463). The following 
prognostic factors were analysed to assess their influence on local control and found
to be not significant: stage (IIB vs. IIIB) (p=0.995), age above and below 50 years
(p=0.532), treatment duration (p=0.6508), and number of fields used (p=0.603). The 
adverse effects of radiation-induced toxicity depended on age group (p=0.01), 
number of fields (p=0.001), and BED Gy3 dose to organ at risk were statistically 
significant (p=0.001). The rectal, grade 3 and 4 radiation induced toxicity were 
observed to be increased when the BED Gy3 dose was above 105 Gy3. Similarly,
bladder grade 3 & 4 toxicity rate were increased with BED Gy3 dose of 120 Gy3
(p=0.001).
Conclusion
Limiting the number of HDR brachytherapy applications from 4 or 3 to 2 fractions
has the potential benefit of improving patient compliance. Two HDR applications of 
9 Gy each is most cost effective and resource sparing to the institution compared to 3 
or 4 insertions.
This study showed that 9 Gy  2 fractionations HDR brachytherapy with concomitant 
chemo-radiotherapy was equally effective in short term local control and incidence of 
treatment related complications compared to other 2 fractionation regimens during 6 
months follow up. 
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INTRODUCTION
Carcinoma of the uterine cervix is the second most common neoplasm in women 
worldwide and is the most frequent cancer among women in Africa, Asia and South 
America [1]. It is the most common malignancy in South African black and coloured 
females with a lifetime (1 – 74 years) risk of 1 in 41 and the 2nd and 5th most common 
cancer in Asian and white females, respectively[2] . Over the past decade, between 
550 and 640 new patients with carcinoma of the cervix were seen at Johannesburg 
Hospital annually[3] .
Radiotherapy (RT) plays a major role in the treatment of invasive uterine cervical 
carcinoma. Early invasive tumours are managed with either radical surgery or RT. 
Locally advanced tumours are also treated with RT. Optimal treatment results require 
a combination of dedicated planned external beam RT (EBRT) and intracavitary 
brachytherapy (ICRT). The curative potential of radiotherapy in the management of 
carcinoma of the cervix is greatly enhanced by the use of intracavitary brachytherapy. 
The success of brachytherapy may be attributed to the delivery of a high radiation 
dose to the tumour while sparing the surrounding normal tissues[4].
Low-dose-rate (LDR) ICRT has a long history in the treatment of cervical cancer. 
The term “brachytherapy” refers to a strategy of implanting sealed radioactive 
sources either in close proximity to or in contact with the target tissue. High-dose-rate 
(HDR) brachytherapy was initiated in the late 1950s with a radiation source of 60Co 
and has been increasingly used for the treatment of cervical cancer[5].
The use of HDR brachytherapy is the result of technological developments in the 
manufacture of high-intensity radioactive sources, sophisticated computerized remote 
after loading devices and treatment planning software. Several advantages of HDR 
brachytherapy, including rigid immobilization, outpatient treatment, patient 
convenience, accuracy of source and applicator positioning, individualized treatment 
with source optimization and complete radiation protection for personnel have been 
claimed[4][6]. These factors have promoted the outpatient management of HDR 
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brachytherapy procedures and have increased the possible number of brachytherapy 
procedures that can be performed daily. However, the move to HDR brachytherapy 
significantly increases the expenses for staff, equipment and need a change of the 
iridium source every three months.
External beam radiotherapy
RT is the cornerstone and the treatment of choice for Federation International de 
Gynaecologic et Obstetrique (FIGO) stage IIB, IIIA, IIIB or IVA carcinoma of the 
cervix and is an excellent alternative to surgery in selected patients with stage IA, IB, 
or IIA diseases[4],[7]. RT for primary cervical cancer consists of a combination of 
EBRT and brachytherapy, except in the stage IA disease where brachytherapy alone 
may be used[7].
Ideally, pelvic radiotherapy begins with EBRT, which is designed to shrink the 
primary tumour and to improve the geometry for the brachytherapy insertions that 
follow. The pelvic field is usually 15 cm by 15 cm, extending to 2 cm laterally to the 
bony pelvis and inferiorly to the border of the obturator foramen or 2 – 3 cm below 
the lower tumour extent. The superior margin can be extended to cover the common 
iliac nodes or even higher if Para-aortic lymph node metastases are evident[8].
Brachytherapy 
A number of studies have shown that HDR brachytherapy with concomitant chemo-
radiotherapy is safe and effective in the management of cervical cancer[9]. In different 
countries and centres, various fractionation regimens have been studied. In a paper 
presented by Patel et al (1992), 412 patients diagnosed with stage III or large stage I 
and II, biopsy proven cancer of the cervix were treated with EBRT and then 
randomized to receive either HDR 18 Gy in 2 fractions of 9 Gy each or 35 Gy by
continuous application of LDR brachytherapy. The five years survival, local control, 
and distant failure were not significantly different and there was no evidence of 
increased toxicity in HDR brachytherapy group[10].
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A study done in Bangkok Thailand[11] which comparing LDR and HDR
Brachytherapy in the treatment of invasive uterine cervical cancer, showed that the 3
years overall survival rate for the LDR and HDR was 70.9% and 68.4% (p = 0.75) 
respectively. Subgroup analysis stratified by stage showed non-statistically 
significant differences in terms of overall survival, pelvic control and relapse free 
survival rates between the two groups. The high number of distant failures suggests
that other modalities such as systemic concurrent or adjuvant chemotherapy might 
improve results, especially in patients with stage IIB and IIIB disease.
Over the last decade, the treatment of cervical carcinoma with radiation has become 
increasingly sophisticated with evidence-based guidelines generated from randomized 
trials. In contrast, radiation therapy techniques, including the design of treatment 
fields, total dose of EBRT and BT, timing of BT, type of implant, dose rate, and ways 
of evaluating the quality of treatment have been based on past clinical practice. 
Several authors have reported on the inadequacy of EBRT alone in maximizing local 
control. In analysis of 565 patients with varies stages of cervical carcinoma treated in 
the Patterns Care Study, Coia et al reported improved survival (67%) and pelvic 
tumour control (78%) for patients receiving intracavitary BT than for patients who 
had no intracavitary BT application, for whom the 4-year survival rate was 36% and 
the in-field failure rate 57%[12][13]. Hanks reported a higher incidence of pelvic 
recurrences in patients with stage III cervical carcinoma treated with external beam 
alone than in patients who received BT in addition to EBRT. Figure 1 shows the local 
control rates with EBRT alone compared to a combination of EBRT and BT[12].
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Figure 1. Carcinoma of uterine cervix: incidence of central or pelvic recurrence[12]
High Dose Rate Brachytherapy Fractionation
Various HDR fractionation schedules have been used worldwide in different 
radiotherapy centres. Examples of the various fractionation regimens used are shown 
in Table1 below.
Table 1. HDR fractionation schedules[14]
Author
Whole-pelvic 
dose
HDR fx1 BED Gy10
LQED 2 
Gy/ fx
7 Gy  3 86 Gy10 72
Wong 40 Gy in 20 fx
6 Gy  4 88 Gy10 73
Sood 45 Gy in 25 fx 9 Gy  2 89 Gy10 74
Ferrigno 45 Gy in 25 fx 6 Gy  4 92 Gy10 77
NCIC trial 45 Gy in 25 fx 8 Gy  3 96 Gy10 80
GOG standard 45 Gy in 25 fx 8 Gy  3 101 Gy10 85
ABS 
recommendation
45 Gy in 25 fx
4 to 8 fx
5.3 to 7.5 Gy
98 – 109 Gy10 82 – 91
                                                
1 Fx – fraction, NCIC – National Cancer Institute Of Canada, GOG – Gynaecology Oncology 
Group, ABS – American Brachytherapy Society.
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Sood and colleagues[15][16] reported encouraging results of concomitant chemo-
radiotherapy (CCRT) using HDR-intracavitary brachytherapy (ICBT) for locally 
advanced uterine cervical cancer. They used HDR of 9 Gy each in 2 fractions with 
CCRT and demonstrated an excellent 3 years actuarial local control of 85%. The 
actuarial severe late complication rate ( grade 3) was 6%.
More recently in 2001, a study was done at the Albert Einstein College of 
Medicine[16] which showed that 2 fractions of HDR brachytherapy of 9 Gy each with 
and without concomitant chemo-radiotherapy to the pelvis were safe and effective in 
the management of patients with carcinoma of uterine cervix. Patients were treated 
with a median dose of EBRT of 45 Gy in 1.8 Gy per fraction daily. This was 
followed by a parametrial boost in patients with disease extension to the parametrium
or to the pelvic sidewall to the median dose of 9 Gy, while the midline structures 
were shielded. The local control rate and rates of complications were similar to those 
reported by Patel et al[10][12].
Several randomized studies have demonstrated that CCRT significantly improves the
treatment outcome compared to radiotherapy alone for patients with locally advanced 
uterine cervical cancer[17][18]. The efficacy of CCRT in the treatment of cancer of the 
cervix has been confirmed by five phase III randomized studies as published in the 
New England Journal of Medicine in 1999[17]. As can be seen from Table 2, four out 
of five studies used brachytherapy in addition to the EBRT concurrent 
chemotherapy[19].
In recent years HDR brachytherapy with EBRT has become popular in the 
management of carcinoma of uterine cervix, because it eliminates many problems 
associated with LDR brachytherapy[20][21]. The number of HDR brachytherapy 
fractions recommended by American Brachytherapy Society (ABS)[22] panel as 
shown in Table 1 ranged from 4 to 8; but as proven and shown by some studies, even 
two fractions of HDR brachytherapy in addition to the EBRT are safe and effective in 
the management of this disease.
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The planning target volume (PTV) of brachytherapy in principle must encompass the 
extent of primary tumour plus a safety margin. The treated volume is limited by the 
maximum tolerance of critical organs. Thus, in extended disease, the whole primary 
tumour extent may not be completely covered by the treated volume and would not 
get an adequate dose to control the disease. The isodose curve distribution of EBRT
and BT as well as dose limiting structure around the GTV were mentioned as the 
main factors leading to an inadequate dose to the tumour volume.
In definitive radiotherapy, the target volume is usually related to the GTV at the 
diagnosis and /or at the time of brachytherapy. For the tumour, extension to the 
proximal part of the parametria (proximal stage IIB) must be included in the CTV as 
far as possible taking into account the dose to critical organs. In cases where the 
tumour extends far into the parametria (distal stage IIB) there is no clear agreement 
on the determination of the CTV for the brachytherapy. Endocavitary brachytherapy 
alone can only cover the tumour extension, which is directly adjacent to the cervix. 
For the above reasons, the University of the Witwatersrand Radiation Oncology 
Department modified FIGO staging system as following. Stage IIB cancer of the 
cervix, subdivided in to two groups: proximal stage IIB(proximal), and distal Stage 
IIB(distal) and; stage IIIB was further divided in to 3 subgroups; early- to those with 
one side pelvic wall involvement, intermediate- bilateral pelvic side wall involvement 
with out hydronephrosis and late – those who have hydronephrosis. Among those 
stage IIB (distal) and IIIB (early), according to departmental protocol are treated 
radically and have been included in this study.
Table 2 Randomized Trials of Concurrent Chemotherapy with External Beam and Brachytherapy in Cervical Cancer[19]
Trial Stage
No. of 
patients
Treatment Arm Brachytherapy Median FU OS in% DFS in %
Morris et. al
RTOG 90-01
IIB-IVA; IB/IIA > 5 cm 193 RT2, CDDO & 5-FU YES 43 73 67
Whitney 193 RT YES 58 40
GOG 85
IIB-IVA
177 RT, CDDP &5-FU YES 91 55 57
191 ROTH YES 35 43 47
176 RT & CDDP YES 70 67Rose et al
GOG 120
IIB-IVA
173
RT, CDDP,
5-FU&HU
YES 69 64
177 RT & HU YES 35.7 45 47
183 RT & CDDP, EFH YES 83 79
Key et al
GOG 123
IB Bulky
186 RT & EFH YES 74 63
                                                
2 RT – Radiotherapy, CDDP – Cisplatin, 5-FU – Fluorouracil, HU – Hydroxyurea, EFH – Extra facial hysterectomy, OS – Overall survival, DFS –
Disease free survival, FU – Follow-up.
Radiobiology and Physics of Brachytherapy
Based on the linear quadratic model, the biological effective dose (BED) to point A is 
a contribution from EBRT and HDR brachytherapy. The BED for the tumour may be 
determined for tumours using an / ratio of 10, which is used for early responding 
tissues. The total BED at rectal and bladder reference points may be determined by 
using an / ratio of 3 which is used for late responding tissues. The equation written 
below may be used in the calculation for total BED dose to gross tumour volume 
(GTV) as a contribution of both EBRT and brachytherapy as well as to critical organs 
(rectal and bladder) as seen in appendix c[16].
ICRU reference points
Brachytherapy for cervical cancer is based on intrauterine and or intravaginal sources.
Intracavitary therapy is often used in combination with external beam therapy. In 
particular, it would be desirable, whenever possible, to use the concept of target 
volume, treatment volume, and irradiated volume as defined for external beam 
radiotherapy. However, due to the high dose-gradient around the source (throughout 
the tumour and target volume), the specification of the target absorbed dose in terms 
of dose absorbed either at one or several reference points within the target volume is 
not considered meaningful. Therefore, the approach used in external beam therapy 
cannot be used[23]. Based on clinical experience, different systems for the treatment of 
cervical carcinoma have been proposed. Three basic systems have been developed;
the Stockholm system, the Paris system, and the Manchester system. Systems used 
throughout the world are derived from these 3 basic systems[24].
The Manchester system (Paterson and Parker, 1934), derived from the original Paris 
system, was first utilized in 1920. It was designed to deliver a constant dose-rate to
defined points near the cervix, irrespective of variation in the size and shape of the 
uterus and vagina. In the Manchester system, an application was specified in terms of 
the dose in roentgen delivered at specific points such as point A and B as shown in
Figure 2.
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Figure 2. ICRU point A and point B[24]
Related to rectum and bladder, two reference points are defined which are located 
relatively close to the sources – the ICRU-bladder reference point and the ICRU-
rectum reference points.
Figure 3. Rectum and bladder ICRU reference points lateral view[24]
These points are reproducible and reliable. However, they do not necessarily 
represent the maximum dose to these organs at risk.
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Figure 4. The pelvic wall reference points and the points in the lymphatic trapezoid[24]
Related to bony structures and lymph node topography, 2 set of reference points 
relatively far from the source are defined; the pelvic wall reference points and the 
points in the lymphatic trapezoid (see Figure 4). These indicate the dose to the lateral 
margins of the true pelvis and to the different lymph node regions: external iliac, 
common iliac and low Para-aortic.
Organ at Risk and its Localization
Organs at risk are those whose tolerances and vicinity may affect planning doses; in 
cervix cancer these include the rectum, bladder, urethra, and sigmoid colon. The 
determination and specification of the absorbed dose to organs at risk are obviously 
useful with respect to normal tissue tolerance limits. Chassagne and Horiot[25] have 
proposed reference points for the expression of the absorbed dose to the bladder and 
to the rectum. The bladder reference point is obtained thus: The balloon of a Foley 
catheter is filled with 7 ml of radio-opaque fluid. The catheter is pulled down to bring 
the balloon against the urethra. On the lateral radiograph, the reference point is 
obtained on an antero-posterior line drawn through the centre of the balloon. The 
reference point is taken on this line at the posterior surface of the balloon[24],[25] .
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The rectal reference point may be obtained from the lateral radiograph using an 
anterior-posterior line source or from the middle of the intravaginal source. The point 
is located on this line at 5 mm behind the posterior vaginal wall and can be visualized 
by means of an intra-vaginal mould or by opacification of the vaginal cavity with 
radio-opaque gauze used for the packing. On the AP radiograph, the reference point 
is at the lower end of the intrauterine source or at the middle of the intravaginal 
source[24].
The pelvic-wall reference point[24] can be visualized on an AP and lateral radiograph 
and is related to fixed bony structures. This point is intended to be representative of 
the observed dose at the distal part of parametrium and at the obturator lymph node. 
On an AP radiograph, the following 2 lines intersect the pelvic-wall reference point: 
the horizontal line tangential to the highest point of the acetabulum and the vertical 
line tangential to the inner aspect of the acetabulum[24].
Evaluation of the absorbed dose at the reference points, related to well defined bony 
structures and lymph node areas is particularly useful when intracavitary therapy is 
combined with EBRT.
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ADVERSE EFFECTS
The main complications following the treatment of cancer of the cervix involve the 
bowel and urinary tract, with an overall actuarial five year severe complication rate of 
8 – 10%[20], [26], [27]. Late sequelae of radiotherapy occur mainly during the first 3 – 5 
years following treatment and this rate decreases in subsequent years. Gastrointestinal 
complications usually occur earlier than urinary complications at 30 months versus
48 months[26][27].
There is a continuous risk of all types of complications as demonstrated in Eifel series
of 1784 patients with an estimated rate of 0.34% per year after treatment. Rectal 
complications increased by 1% during the first 2 years and then decreased to 0.06% 
per year; while bladder complications increased by 0.7% during the first 3 years, and 
later it was stabilizing at 0.25% per year[27][28].
Radiotherapy related side effects are categorized as directly linked to either the 
radiotherapy techniques and doses or secondary to other factors such as prior surgery, 
concomitant chemotherapy, or co-morbid condition such as diabetes, hypertension
and pelvic inflammatory disease[26], [27], [28].
Total dose
Perez[29] showed that the most significant factor affecting the incidence of 
complications was the total dose of irradiation to the pelvic organs by both pelvic
irradiation and the intracavitary insertion. The incidence of complications 
significantly increased when the dose exceeded 80 Gy. A more recent analysis with a 
larger number of patients (up to 1456) confirmed the role of total dose in the 
development of complications[26]. For the bladder, a dose below 80 Gy correlated 
with less than 3% probability of morbidity while this rate reached 5% with higher 
doses[24]. The incidence of morbidity from recto-sigmoid complications is 
significantly increased when the total dose exceeded 75 Gy: 4% with doses below 75 
Gy and 9% with higher doses. The dose to the lateral pelvic wall was a significant 
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factor influencing the small intestine complication rate: the complication rate was less 
than 1% with a total of 50 Gy or less, 2% with 50 to 60 Gy, and 5% with higher 
doses[30].
Volume
Using a combined EBRT and brachytherapy approach, the complications observed 
are closely correlated with the volume treated. Barillot[30] reviewed 642 patients 
treated between 1970 and 1994 with radiotherapy alone for uterine cervical 
carcinomas. The analysis was divided into 3 periods. Comparisons of the 3 time-
periods showed a significant reduction of the external radiation dose, in the use of a 
parametrial boost, the use of vaginal cylinders and the height, width, and thickness 
volume[30]. The rate of grade 3 complications dropped from 16% to 6% over time[29].
Influence of Dose Rate
Stage for stage the local control rates in the LDR and HDR groups were 
similar[22],[24]. The overall local control achieved in the LDR group was 79.7% as 
compared to 75.8% in the HDR group. The five-year survival figures in the LDR and 
HDR groups were also comparable[31]. 
The only statistically significant difference found was in the incidence of overall 
rectal complications. These were 19.9% for the LDR group, compared to only 6.4% 
for the HDR group. However, the incidences of more severe grade 3 – 4
complications were not significantly different between the 2 groups (2.4% versus
0.4%) respectively[29]. In addition, HDR brachytherapy has some advantage over 
LDR brachytherapy in cancer of cervix[22][29]. These advantages may be listed as 
follows:
A. HDR eliminates radiation exposure hazard for caregivers, visitors and 
eliminates the need for source preparation and transportation.
B. HDR allows for shorter treatment times that results in;
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I. Less patient discomfort, because prolonged bed rest is eliminated.
II. It is possible to treat patients who may not tolerate long periods of 
isolation and those who are at risk for acute cardiopulmonary toxicity 
due to prolonged bed rest.
III. There is lower risk of applicator movement during therapy.
IV. Reduced hospitalization (due to outpatient therapy) results in cost 
shifting.
V. Possibly allows greater displacement of nearby normal tissues (by 
packing or using rectal retractor), which could potentially reduce the 
rectal and bladder morbidity.
VI. It is possible to treat a larger number of patients in institutions that have 
a high volume of cervical cancer patients but insufficient inpatient 
facilities (for example, in some developing countries).
C. Allows the use of smaller diameter sources than are used in LDR;
I. This reduces the need for dilation of the cervix and the need for heavy 
sedation or general anaesthesia. High-risk patients who are unable to 
tolerate general anaesthesia may now be more safely treated.
II. It is physically easier to insert applicator into the cervix.
D. Allows for treatment-dose-distribution optimization. The variation of dwell 
time with the single stepping source strength and source positions allows for 
greater control of the dose distribution and potentially less morbidity.
E. Allows integration of EBRT and HDR, which can lead to a shorter overall 
duration of treatment and potentially to improved tumour control.
The curative potential of radiation therapy in the management of carcinoma of cervix 
is greatly enhanced by the use of intracavitary brachytherapy. The correct application 
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and execution of the brachytherapy component of radiotherapy is crucial for 
maximizing the local control of cervical cancer[12].
Table 3. Criteria for optimal application in the intracavitary brachytherapy[12]
Criteria for optimal application in intracavitary brachytherapy
Anterior posterior view
Colpostats high in the fornices along cervix
Radio-opaque markers placed on exocervix corresponding to the flange on the 
central tandem
Tandem mid line; unrotated
Tandem midway between colpostats
Lateral view
Tandem bisect the colpostats
Sufficient anterior and posterior packing
Foley balloon identified at vesico-urethral junction
The influence of brachytherapy technique has been assessed by a number of centres. 
Perez found a correlation of poor insertion technique with an increment in the 
incidence of central failure[29].
Intracavitary gynaecological brachytherapy is typically standardized with the 
application techniques and dosimetry for a given geometry. This defined loading 
technique, usually derived from radium loading pattern, creates a pear-shaped 
distribution when viewed from anterior-posterior and a banana shaped distribution on 
lateral view[4].
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Figure 5. Lateral and anterior-posterior views of isodose distribution of brachytherapy 
application
[6]
Standard dose distribution of brachytherapy application in Figure 5 above shows the
100%, 50%, and 200% isodose lines with a standard Manchester applicator with an
ovoid. Point A is the reference point in these standard programs where the dose is
prescribed. Limitations are set for the dose to the critical organs: The dose to the 
ICRU rectum reference point should be less than 70% of the dose at point A and the
dose to the ICRU bladder reference point should be less than 80%. As the positions of 
the rectum and the bladder are radiographically known relative to the application and 
the gross tumour volume (GTV), these limitations apply for each brachytherapy 
fraction[4].
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BACKGROUND TO THE STUDY
Most of the patients seen at The University of the Witwatersrand (WITS), Radiation 
Oncology Department outpatient clinics are diagnosed to have locally advanced 
cancer of cervix (stage II and III)[3]. These patients, according to the department 
protocol, are treated with 3 or 4 brachytherapy insertions in addition to 50 Gy 
external beam radiotherapy.
In respect to the management of patients with locally advanced cancer of the cervix,
this study was designed to investigate the following; 
1. 18 Gy in 2 fractions of HDR brachytherapy is effective and leads to an equivalent 
local control compared to 24 Gy in 3 fractions and 26 Gy in 4 fractions,
2. the toxicity of treatment using 18 Gy in 2 fractions of HDR brachytherapy is 
equivalent to the other 2 regimens.
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OBJECTIVES
1. To compare the local control with the following 3 HDR brachytherapy 
fractionation regimens: (a) 2 fractions of 9 Gy each; (b) 3 fractions of 8 Gy 
each and (c) 4 fractions of 6.5 Gy each, with concomitant chemo 
radiotherapy,
2. To compare the normal tissue complication rate using these 3 regimes
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METHODS AND MATERIALS
Inclusion criteria
1. Biopsy proven squamous cell carcinoma, adenocarcinoma, adenosquamous 
carcinoma of the cervix,
2. Age above 20 and below 75,
3. Performance status ECOG 0 up to 2 (see Table 4),
4. HIV negative,
5. Carcinoma of the cervix FIGO stage IIB (distal) and IIIB (early) , and
(see Appendix D)
6. Reliability of the patient for follow up
Table 4. Criteria for performance status on the ECOG performance scale[32]
Scale Description
0 Normal activity, asymptomatic
1 Symptomatic; fully ambulatory
2 Symptomatic; in bed less than 50% of time
3 Symptomatic; in bed more than 50% of time, not bedridden
4 100% bedridden
Exclusion criteria
1. Age greater than 75,
2. Lower third vagina involvement
3. Patients unavailable for follow up,
4. Metastatic disease,
5. HIV positive patients,
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6. Previous hysterectomy,
7. Previous pelvic radiotherapy,
8. Malignancy other than skin cancer not controlled for five or more years,
Justification for exclusion and inclusion criteria
A cut-off age of 75 was selected as these patients often have co-morbidities with 
limited life expectancy. In addition to this, concurrent chemotherapy is not given 
routinely to this group of patients according to departmental practice. Patients with 
lower third vagina involvement were excluded because brachytherapy is 
individualised for these patients and the isodose distributions produces are not 
comparable with the standard technique. Patients with Stage IIIB extending to both 
pelvic sidewall or with hydronephrosis were excluded because they are not treated 
radically according to the departmental treatment protocol.
Diagnostic work up
1. History and physical examination that included a bimanual pelvic and rectal 
examination,
2. Cervical biopsy,
3. Full blood count, platelet, urea, and electrolytes,
4. Chest radiography,
5. Abdominal sonar,
6. HIV test, and
7. Cystoscopy and proctosigmoidoscopy (only if clinically indicated).
See appendix D for staging [33][34]
Note: According to the departmental protocol, both stage IIB (distal) and IIIB (early) 
will get the same radical dose of EBRT and HDR.
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All patients fulfilling the inclusion and exclusion criteria received 50 Gy in 25 
fractions of EBRT, and were then, randomized to one of the following three Arms.
Arm I.
Patients received HDR brachytherapy of 4 fractions of 6.5 Gy each. The 
brachytherapy was given once weekly during the last 4 weeks of EBRT with 
concomitant chemotherapy.
Arm II
Patients received HDR brachytherapy of 3 fractions of 8 Gy per fraction to point A. 
The HDR brachytherapy was given during the last 3 weeks of external beam 
radiotherapy with concomitant chemotherapy.
Arm III
Patients received HDR brachytherapy of 2 fractions of 9 each, with concomitant 
chemo radiotherapy. 
In this study, randomization table were used to assign patients to 1 of 3 groups 
sequentially. Patients randomized to receive HDR brachytherapy of 2 fractions of 9 
Gy each; brachytherapy was given weekly during the last 2 weeks of external beam 
radiotherapy with concomitant chemotherapy.
The departmental treatment field protocol for EBRT depended on the anterior-
posterior separation of each patient. Every patient received either anterior and 
posterior fields or anterior, posterior, and two lateral fields from either side.
During treatment, the patients were assessed weekly for side effects. Each HDR 
brachytherapy application was evaluated individually. A rigid intrauterine tandem 
(nucleotron 6 cm, 4 cm, or 2 cm in length) and a ring applicator (nucleotron 3.4 cm, 
3.0 cm, or 2.6 cm in diameter) with a rectal shield were used. The length of the 
tandem and the diameter of the ring were individualized for each patient. Two 
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orthogonal radiographs with a dummy source in the applicator were taken (see Figure 
6). Transparencies of appropriate magnification indicating the isodose distributions 
were placed over the applicator image on the screen. This was used to check the 
isodose distributions. The rectum and the bladder points were calculated according to 
the ICRU 38 recommendations. From lateral radiograph, the anterior rectal wall was 
identified with the help of a radio-opaque balloon and the posterior wall of bladder 
was identified using an indwelling catheter with contrast material in its balloon.
Figure 6. Two orthogonal radiographs of the applicator in situ
The pelvic sidewall reference point was visualized on an anterior-posterior 
radiograph related to a fixed bony structure (acetabulum). This point was intended to 
be representative of the absorbed dose at the distal part of parametrium and at the 
obturator lymph node.
The doses to critical organs (rectum and bladder) were calculated by measuring the 
distance from the applicator to ICRU reference points from the graph after correcting 
for the magnification factor. The graph was plotted for each ring size and tandem 
length.
Figure 7 shows the relationship between the percentage dose prescribed to point A 
against distance from applicator, ring size 34 and tandem size 46, to the ICRU 
rectum, bladder, and pelvic sidewall points.
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Figure 7. R34IU46 rectal, bladder and PSW reference points (the relationship between the 
percentage dose to point A and distance from the tandem to ICRU rectum, bladder, and pelvic 
sidewall points)
By using packing with each application, an attempt was made to increase the distance 
between the tandem and critical organs. As can be seen from the graph, the dose to 
the critical organ is inversely proportional to the distance square away from the 
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tandem. For each HDR application, a calculation was done by measuring the distance 
from the tandem to the organ at risk by using the magnification factor, and the graph 
for the bladder, rectum, and the pelvic sidewall points.
For each arm, the contribution of point A dose was calculated as per the linear 
quadratic model (LQM)[35] from both external beam radiotherapy and intracavitary 
portions of the treatments. The total biologically effective dose (BED) to the tumour 
was calculated by using an / ratio = 10 (Gy10) (see Table 5).
The BED Gy10 can be converted to a linear quadratic effective dose (LQED) for a 2 
Gy fraction by dividing the BED dose by 1.2 (the relative effectiveness for a 2 Gy 
fraction)[23].
Table 5: BED Gy10 dose to point A for 3 HDR fractionation regimens
Arm
EBRT
Dose Gy/fx3
EBRT
No. fx
HDR
Dose Gy/fx
HDR
No. fx
Gy10
Point A
LQED Gy10 to 
point A 2 Gy/fx
I 2 25 6.5 4 103 86
II 2 25 8 3 103 86
III 2 25 9 2 94 78
The median BED for late responding tissue for arm I patients was 165 Gy3.With 
adequate packing and good application, the bladder and the rectum would usually 
receive 60 – 80% of the prescribed dose to point A. If the normal tissues received 
70% dose, then the 165 Gy3 term would reduce to about 115 Gy3. The LQED
[6][23] for 
a 2 Gy fraction to late responding tissue can be calculated by dividing the BED by 
1.67 (the relative effectiveness for a 2 Gy fraction to the late responding tissues , 115 
Gy/1.67= 69 Gy. This is shown in Table 6 for 3 HDR fractionation schedules.
                                                
3 Fx - fraction, Gy - Gray, No - number, LQED - Linear Quadratic Effective Dose.
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Table 6: BED Gy3 dose and to late responding tissue for three fractionation regimens
Arm
Gy3 dose to 
Point A
70% of BED dose in 
Gy3 to organ at risk
Late responding tissue LQED in 
Gy3 at 2 Gy/fraction to organ at risk
I 165 115 69
II 171 120 71
III 155 109 65
After the completion of the treatment, patients were assessed at 6 weeks in order to 
evaluate response and acute side effects. At 6 months post–therapy, the patients were 
further assessed for any side effects and the response to the treatment by doing a Pap
smear.
In this study, the treatment outcome and complication were assessed in each arm 
using the following criteria:
1 The local control of the disease by a Pap-smear at six months post treatment in 
each arm,
2 The effect of stage, age, ring application and duration of treatment on local 
control,
3 Toxicity in each arm,
4 The effect of age and number of fields treated on radiation induced toxicity,
5 The doses to the bladder and rectal reference points and their association with 
radiation induced toxicity.
The Epi Info program 2002 performed all statistical analysis. Duration of treatment
was measured from the first day of treatment to the end day of treatment. Patient age, 
tumour stage, number of portals and duration of treatment were used as prognostic 
factors for the factors analyses of local control and adverse effects of RT. 
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Comparisons of categorical variables were performed using the Chi-square test, t test 
and for more than 2 variables, Analysis Of Variance (ANOVA) test was used. 
Statistical significance was considered with p-values of less than 0.05 or 95% of 
significance. 
During the HDR application, the widest ring and the longest tandem were used when 
possible depending on the individual patient anatomy. The size of applicator or the 
length of the tandem chosen for this study did not depend on the stage of the patient 
or the size of the lesion, but was dependent on the patient’s anatomy. R26IU66 was 
the smallest width ring that has 2.6 cm diameter and was used for patients who have 
narrow anatomy. R30IU26 was the shortest tandem used for only one patient who had 
fibrosis of the cervix. The length of this tandem is only 2 cm. The majority of patients 
were treated with R34IU66, which has the widest ring (3.4 cm) and the longest 
tandem (6 cm).
SOMA (Subjective Objective Management and Analytic) scale was used to assess 
and treat the toxicity induced by radiotherapy[36]. (See appendix B)
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RESULTS
Seventy-one patients were entered in the study. Three patients were excluded due to 
active non-malignant diseases. One patient had active tuberculosis and 2 patients had 
severe skin reactions and herpes zoster. A repeated HIV test in the latter 2 patients
confirmed that they were HIV positive. Two patients withdrew following the first 
HDR application. The remaining 66 patients were further analysed.
Twenty-two patients were recruited to Arm I; twenty-three to arm II and twenty-one
arm III. Sixty-six patients completed the prescribed dose of radiotherapy but only 
fifty-nine had the six-week and the six-month prescribed evaluation and Pap-smear, 
and were further evaluated. Of these, thirty-nine (59%) were stage IIB (distal) and 
twenty-seven (41%) stage IIIB (early).
All 66 patients received HDR and 59 received concomitant cisplatin 80 mg/m2 3
weekly. The reasons for not receiving chemotherapy (n=7) were low creatinine 
clearance in 4 patients, 2 could not receive chemotherapy for logistic reasons and 1 
patient absconded. Among those 7 patients, 3 of them were in arm I, 2 were in arm II 
and 2 were in arm III. The only chemotherapy-related side effect noted was mild to 
moderate nausea and vomiting.
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Figure 8. Distribution of patients in each Arm
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Further analysis will include only those 59 patients who completed the prescribed 
dose of chemo radiotherapy and attended the six week and six month assessments and 
Pap smear.
The distribution of patients by stage and by age group at diagnosis in the various 
arms was as shown in table 7 below. 
Table 7. Distribution of patients by stage in each arm
Arm Stage IIB (distal) Stage IIIB (early) Total
I 11 9 20
II 11 10 21
III 9 9 18
Twenty-nine patients were aged 31 – ≤50 years and 30 were aged 51 – 75 years. 
There was no statistical significant difference between the mean ages in the 3 arms 
with p value of 0.995 using the ANOVA. There was no statistically significant 
differences between 3 arms in terms of stage distribution and the number of 
chemotherapy cycles given using the Chi-Square test (p=0.678 and 0.532 
respectively). 
The mean time to completion of treatment was 46.4 days with a range of 35 – 58
days. The duration of treatment was similar in the three arms according to ANOVA 
test with p value of 0.6508. Ninety-three percent of the cases were squamous cell 
carcinomas, 5% adenocarcinomas, and the rest were adenosquamous carcinomas (fig 
10). Four of non-squamous patients were in arm II and the remaining 2 patients were 
in arm III.
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Number of Chemotherapy Cycles 
Received
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Figure 9. Number of Chemotherapy Cycles Received
One patient received 4 cycles of chemotherapy instead of the standard three weekly 
cisplatin. She received weekly twice (40 mg/m2) followed by three-weekly twice (80 
mg/m2), but the patient did not develop any side effects during treatment and 
thereafter for six months follow up time.
Distribution of Patients by Histology 
squamous cell
adenosquamous
adenocarcinoma
Figure 10. Distribution of patients by histology 
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Treatment outcome
Fifty-nine patients completed the prescribed treatment and were evaluated. Fifty-two
had a good clinical response with negative Pap-smears at 6 months. Seven patients 
had a positive Pap smear with clinical signs of persistence disease. There was no 
statistically a significant difference in response for treatment in 3 arms as seen in 
Figure 11 with p value of 0.464.
91% (3/31) of patients with stage IIB (distal) had negative Pap smears at 6 months 
compared with 84% (4/28) of stage IIIB (early) as shown in Figure 12. This was not 
statistically significant (p = 0.328).
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Figure 11. Local control by treatment arm
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Figure 12. Local control by stage
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Figure 13. Local control among stage IIB (distal) patients in each Arm
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Figure 14. Local control among stage IIIB (early) patients in each Arm
Table 8. Local Control by Age Group
Age 
group
Total number of patients Pap-smear negative Pap-smear positive
31 – 50 28 23 5
51 – 75 31 29 2
(p=0.17)
The number of fields used did not affect local control (p = 0.603) (table 9) nor did the 
duration of treatment (p = 0.402) (table 10).
Table 9. Relationship between Local Control and Number of Fields
Number of fields Pap-smear negative Pap-smear positive
2 31 4
4 21 3
(p = 0.603)
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Table 10 Relationship between Duration of Treatment and Local Control
Duration of treatment Pap-smear negative Pap-smear positive
35 – 45 days 23 4
46 – 58 days 29 3
(p = 0.402)
The adverse effects of radiation observed were compared in each arm. Radiation 
induced grade 3 and 4 bladder and rectum effects were assessed in each arm and 
plotted in Table 11 and Table 12 respectively.
Table 11 Radiation induced bladder toxicity in each arms.
Arms Radiation induced grade 0-2
bladder toxicity
Radiation induced grade 3 & 4 bladder 
toxicity
I 19 1
II 16 5
III 17 1
Table 12 Radiation induced rectal toxicity in each arms
Arm 
Radiation induced grade 0-2 
rectum toxicity
Radiation induced grade 3& 4 bladder 
toxicity
I 17 3
II 19 2
III 15 3
Although the numbers of patients in each age group were nearly equal, of the 12
patients who developed grade 3 and 4 bladder and rectal toxicity, eight patients were 
below the age of 50 (p < 0.001).
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(p < 0.01)
Figure 15 Radiation induced grade 3 & 4 bladder and rectum toxicity in two age groups
The BED to the rectum and bladder ICRU reference point was calculated from both 
EBRT and intracavitary HDR brachytherapy. Patients treated with two fields EBRT 
in addition to the HDR brachytherapy had an increased chance of grade 3 and 4 
toxicity compared to those treated with four fields (p = 0.001).
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Number of Fields and Radiation Induced Grade 3 & 4 
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Figure 16 Relationship between Number of Fields and Radiation Induced Grade 3 & 4 Bladder 
and Rectal Toxicity
More rectal complications were observed in patients who received a BED of 105 Gy3
dose or more.
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Figure 17. Relationship between the rectal dose and degree of toxicity
Radiation induced bladder toxicity increased when the dose to the bladder reference 
point increased.
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The relationship between BED dose to 
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Figure 18. Relationship between the bladder dose and degree of toxicity
In this study, the Gy3 BED dose to the organ at risk that induced grade 3 & 4 of 
toxicity were different in each Arm. The range of BED dose either to bladder or to 
the rectum was high in arm I and low in arm III. Almost all patients who did receive 
the threshold dose mentioned in table 3 developed grade 3 or 4 radiation induced 
toxicity.
Table 13 Threshold BED Gy3 Dose which Induced Grade 3 & 4 Toxicity in each Arm 
Arm
BED Gy3
to bladder 
range
mean
dose to 
bladder
Threshold Dose 
induced grade 
3&4 toxicity in 
Gy3 to bladder
BED 
Gy3 to 
rectum 
range
Mean
dose to 
rectum
Threshold Dose 
induced grade 
3&4 toxicity in 
Gy3 to rectum
I 107-137 119 120 97-120 108 107
II 101-130 118 111 101-123 111 110
III 95-123 110 114 95-123 106 105
In our study the incidence of grade 3& 4 rectum and bladder radiation induced 
toxicity were observed on the patients who had above BED Gy3 dose of 105 and 120 
respectively to the rectal and bladder referral points. 
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Table 14. Incidence of grade 3 & 4 toxicity to the rectum and bladder depending on BED Gy3
dose in Arm during six months
Site Variable
Category
Gy3
Incidence of grade 
3&4 toxicity
 105 5%
Rectum Total BED at rectal point
 105 10.2%
 120 7%
Bladder Total BED at bladder point
120 15%
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DISCUSSION
Despite screening programs, cervical carcinoma remains a major health problem 
throughout the world. Until recently, pelvic radiation has been the standard therapy 
for advanced disease with overall five-year survival rates of 50%. Recently, 5
randomized trials demonstrated a significant survival advantage for the concomitant 
administration of radiotherapy and cisplatin-based chemotherapy[7].
Radiation therapy to cancer of the cervix is delivered with EBRT and BT. It is an 
alternative to surgery in stage I, IIA, and IVA and comparable survival and tumour 
control with either modality have been reported[37]. Several prognostic factors, 
including tumour stage, volume, age of patient, performance status, and presence of 
metastatic pelvic, para-aortic lymph nodes, have been shown to affect the therapeutic 
outcome[20].
A variety of technical factors has been found to influence the morbidity of radiation 
therapy in patients treated for carcinoma of the uterine cervix. Among these are the
dose of irradiation, quality of the intracavitary insertion, type of application used and 
proportion of external beam or brachytherapy dose delivered. Host-related factors, 
such as the age of the patient, the presence of diabetes mellitus, hypertension, pelvic 
inflammatory disease and a history of prior surgery have also been reported to affect
the incidence of complications[9], [29], [38].
Patients with extensive loco regional disease have a high rate of local relapse if 
treated surgically. For this reason, patients with stage IIB, III, and IVA tumours are 
treated with radiotherapy, which results in five-year survival rate of 65, 40, and less 
than 20 percent, respectively[37] .
In studies[23], tumour stage was a marginally significant factor for five-year actuarial 
local control with p value of 0.09. The treatment of FIGO stage IIIB carcinoma of the 
cervix poses special problems for the radiation oncologist[28]. The tumour volume is 
usually large, and the likelihood of regional metastasis is high. As a result, clinicians 
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tend to emphasize the role of EBRT more than they would for earlier stage diseases, 
arguing that an emphasis on ICRT results in relative under treatment of the tumour
extending toward or involving the pelvic sidewall. However, the results of a study
done by Mark D. Logsdon and colleges[28] provides convincing evidence that ICRT is 
a critical component of successful treatment of stage IIIB disease. In the literature, 
the survival and local control rate of stage II patients was better than that of stage III 
patients. In the current study, 59 patients were analyzed 57.6% of whom were stage 
IIB (distal) and the remainder (42.4%) were stage IIIB (early). The response to 
treatment at 6months was 91% vs. 86% for stage IIB and IIIB (early) respectively
which was statistically not significant (p = 0.328).
In previous years, different studies have shown that HDR brachytherapy with 
concomitant chemo-radiotherapy is safe and effective in management of locally 
advanced cervical cancer. Patel et al (1992)[10] studied 412 patients diagnosed with 
stage III cancer of the cervix treated with EBRT. Patients were randomized to receive 
either 18 Gy in two fraction of nine Gy each or 35 Gy by continued low dose rate BT. 
the 5 years survival, local control and distant failure were not significantly different 
and there was no evidence of increased toxicity in HDR group. More recently at the 
end of 2001 a study done in Albert Einstein College of Medicine[16] showed that 2
fraction of HDR brachytherapy of 9 Gy each with concomitant EBRT to the pelvis 
provided similar local control with out increasing toxicity. In the current study, the 
local control rate based on 6 months clinical finding and Pap-smear result did not 
show any statistically significant differences when comparing the 3 brachytherapy 
fractionation regimens.
According to a univariate analysis done in Brazil, the overall treatment time with 
cohort value of 50 days was a statistically significant factor for five years actuarial 
local control rate (84% versus 53%, p = 0.008)[23]. The over-all treatment duration 
has been reported by several authors to be of prognostic significance in patients with 
cervical cancer treated by radiation therapy[12][39]. The American Brachytherapy 
Society (ABS)[21][22] recommends keeping the total treatment duration to less than 8 
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weeks, because prolongation of total treatment duration can adversely affect local 
control and survival[12], [39], [40]. In this study, the duration of treatment did not 
influence significantly on local control, but the follow up time is too short to assess 
definitively the local control as only response was assessed at 6 months.
In a study done by Robson Ferrigno and collages shows that patient’s age with cohort 
value of fifty years did not influence the actuarial local control (p = 0.99)[23]. In 
addition to that, this study has shown that local control did not have any dependency 
on age group of the patient, duration of treatment or by using two (AP-PA) or four 
fields (AP-PA and 2 Lat). The main reason why this study differs from others may be 
small number of patients and very short follow up period.
A retrospective study done in Japan showed[37] that concurrent chemo-radiotherapy 
using HDR-ICBT is feasible and efficacious for patients with loco regionally
advanced uterine cervical cancer. They demonstrated that those patients who received 
a cumulative rectal BED of more than 100 Gy3 had significantly higher incidences of
proctitis than those who received less than 100 Gy3 (p = 0.013). The median BED 
values at the ICRU 38 rectal reference point was 94.1 Gy3 (range: 78.3 – 116.1 Gy3).
The low rectal BED value may have favourably affected the incidence of severe
rectal complications[16].
Similarly, a study done in Brazil[23] as shown in Table 15 found that the 5 years 
actuarial incidence of late complication depends on total BED dose to the organ at 
risk.
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Table 15. Five years actuarial incidence of late complication based on BED dose to bladder and 
rectum[23]
Site Variable
Category
Gy3
Incidence in %
 110 12
Rectum Total BED at rectal point
110 18
 125 9
Bladder Total BED at bladder point
 125 17
The significant correlation was found between the dose calculated and measured at 
the rectal point defined by the ICRU and the incidence of late rectal complications. 
Using the linear quadratic model, they established a threshold value for the possibility 
of developing late rectal complication of 125 Gy3, which is unrelated to the number 
of HDR fractions but rather to the total dose delivered to the rectal point by the 
combination of EBRT and HDR brachytherapy. Thus, keeping the biologically 
effective dose below 125 Gy3 at the defined ICRU rectal point will minimize the risk 
of late rectal toxicity. The late rectal damage is a function of total biological effective 
dose to ICRU rectal point and not of the number of HDR BRT fractions[23].
In our study, as shown in Table 14, the biological effective dose, which causes grade 
3 and 4 bladder and rectum toxicity appears to be lower than the previous study done 
in Brazil[23]. The follow up of this cohort of patients is too short to comment on the 
incidence of rectal complication and more follow up is required.
In general, there is more variability in the rectal dose reports. As in some series, the
point for calculation of the rectal dose is pre-determined and others take into account 
several points along the anterior rectal wall. Nevertheless, the different series do 
show a correlation between rectal dose and complications[20]. In spite of the variations 
in the way the rectal doses are calculated, a cumulative dose of 75 Gy can result in a 
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10% incidence of proctosigmoiditis. With higher rectal doses, the incidence of 
proctosigmoiditis also increases[36][41].
Esche et al[42][36] showed that the frequency and severity of proctitis increases with 
cumulative rectal doses and volume treated. The majority of the recto-sigmoid 
complications occurred with cumulative rectal dose in excess of 70 Gy. Perez et al,
has reported on the correlation of the dose with genitourinary and recto-sigmoid 
complications. In this study, the frequency of the grade II and III irradiation induced 
complications with bladder and rectal doses of 80 Gy is 5% but rises steeply with 
doses above this level.
In this study, grade 3 and 4 rectal complications increased when the dose to the rectal 
reference points was beyond 105 Gy3. The chance of grade 3 and 4 bladder 
irradiation induced toxicity increased when the dose to the bladder reference point 
was above 120 Gy3. The rate of radiation induced grade 3 and 4 bladder and rectal 
toxicity increased in those patients received prescribed EBRT in two fields than four 
fields. Among 12 patients who developed grade 3 and 4 radiation induced toxicity,
seven of them were stage IIIB and the remaining five patients were stage IIB.
There are usually limitation factors in most of the studies with the respect of to the 
analysis and data may affect the accuracy of the results. Limitation of this study 
(limited frame time, limited number of patients, 2-D treatment planning and 
inaccurate orthogonal films) are the possible causes of some of the results differing to 
the other studied that are done previously.
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CONCLUSION
Careful attention to normal tissue doses such as the rectum, bladder, and small bowel 
is important when brachytherapy is combined with concomitant chemo-radiotherapy 
regimen in the treatment of locally advanced cervical cancer.
Limiting the number of HDR brachytherapy application from 4 or 3 to 2 may
improve patient comfort and compliance. Two insertions of 9 Gy each HDR 
application was feasible with an acceptable complication rates and equivalent local 
control rates when compared with 6.5 Gy for 4 fractions and 8 Gy for 3 fractions. 
Decreasing the number of fractions of brachytherapy is likely to be cost effective and 
will lead to shorter waiting list of patients and avoiding hospitalization.
Careful attention to radiotherapy technique and planning, such as patient positioning 
and number of portals will minimize both acute and long term toxicity.
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APPENDIX A
Example:-
If a patient with stage IIB (distal) cancer of the cervix receives 9 Gy X 2 HDR and 50 
Gy EBRT in 25 fractions – 2 Gy per fraction. The total rectal BED dose will be:
= 25  2 [1 + 2/10] + 9  2 [1 + 9/10]
= 60 Gy10 + 34.2 Gy10
= 94.2 Gy10 for early responding tissues
= 25  2 [1 + 2/3] + 9  2 [1 + 9/3] 
= 83.3 Gy3 + 72 Gy3
= 155.3 Gy3 for late responding tissues
However, assuming that the ICRU rectum reference point does not receive the full 
brachytherapy dose, as the isodose curve is flattened posterior, and the rectal point 
receives only 80% of the prescribed dose. 80% of 9 Gy is 7.2 Gy and that is the dose 
to the rectum per fx; 7.2  2 (1 + 7.2/3) = 48.9 Gy3 and will receive a total BED dose 
of 83.3 Gy3 from EBRT + 48.9 Gy3 from HDR = 132.2 Gy3
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APPENDIX B
 Grade 1 represents the most minor symptoms that require no treatment,
 Grade 2 represents moderate symptoms, requiring only conservative 
treatment,
 Grade 3 represents sever symptoms, which have a significant negative impact 
on daily activity, and which require more aggressive treatment.
 Grade 4 represents irreversible functional damage, necessitating major 
therapeutic intervention.
Bladder toxicity
Grade
0 No complaints
1. Mild dysuria
2. Moderate dysuria
3. Severe dysuria, gross haematuria
4. Deep ulcer, fistula
Rectum toxicity
Grade
0 No complaint
1. Tenesmus
2. Moderate diarrhoea
3. Pain less rectal bleeding
4. Deep ulceration, fistula
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APPENDIX C
Total BED = BED (EBRT) + BED (HDR)
Total BED =nd[1+(d/α/β)] + Br [1+(d/α/β)]
 

dndBEDTotal  1)( [16]
Where n = number of fractions in EBRT
d = dose per fraction
Br = total dose of brachytherapy
/ = 10 for early responding tissues and 3 for late responding tissues (See 
Appendix A). 
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APPENDIX D
FIGO staging of carcinoma of uterine cervix[33][34]. 
I Cervical cancer confined to the uterus (extension to corpus should be disregarded).
IA Pre–clinical invasive carcinoma, diagnosed by microscopy only.
IA1 measured stromal invasion < 3 mm in depth and < 7 mm in horizontal spread.
IA2 measured stromal invasion > 3 mm and not > 5 mm with horizontal spread of < 7 
mm.
IB clinically visible lesion confined to the cervix or microscopic lesion > IA2.
IB1 clinically visible lesion < 4 cm in greatest dimension.
IB2 clinically visible lesion > 4 mm in greatest dimension.
II cervical carcinoma invades beyond uterus, but not to the pelvic wall or to the lower 
third of vagina.
IIA Tumour without parametrial invasion.
IIB Tumour with parametrial invasion.
III Tumour extends to pelvic wall, and/or involves the lower third of vagina, and/or 
causes hydronephrosis or non-functioning kidney.
IIIA Tumour involves lower third of vagina, no extension to pelvic wall.
IIIB Tumour extends to pelvic wall and/ or causes hyderonephrosis or non-
functioning kidney
IVA Tumour invades mucosa of bladder or rectum and/or extends beyond the true 
pelvis.
IVB Distant metastasis.
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